Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C
TURKISH JOURNAL OF NEPHROLOGY, cilt.29, sa.1, ss.82-83, 2020 (ESCI)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.5152/turkjnephrol.2020.3567
- Dergi Adı: TURKISH JOURNAL OF NEPHROLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.82-83
- Anahtar Kelimeler: Everolimus, toxicity, chronic hepatitis C, ombitasvir/paritaprevir/ritonavir, DRUG-INTERACTIONS
- Akdeniz Üniversitesi Adresli: Evet
Özet
The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug-drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.